Abstract Details

Title 30-Day Readmission Rates of Drug Resistant Epilepsy Subjects Undergoing Operative Intervention – A Single Center Study

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P6 - Poster Session 6 (11:45 AM-12:45 PM)

Poster/Presentation
Number 9-009

Objective We aim to quantify readmission rates following neurosurgical intervention for drug resistant epilepsy (DRE). Readmission risk was also stratified based on type of intervention.

Background Hospital readmissions following index admission have become a commonly tracked quality measure aimed at reducing readmission burden and improving post-discharge care. Though commonly studied in other fields, readmission rates following surgical intervention for treatment-resistant epilepsy have not been quantified thus far.

Design/Methods 30-day readmissions following surgical intervention for DRE at a single major epilepsy referral center were tracked over a five-year period from January 2017 to March 2022. Subjects were stratified into device, resection, or laser interstitial thermal therapy (LITT) groups.

Results Of 570 total subjects, 301 (52.8%) underwent device implantation, 208 (36.5%) underwent tissue resection, and 61 (10.7%) underwent LITT. 94 subjects (17%) were readmitted within 30 days of discharge. 59 subjects (10.4%) were admitted following evaluation in the emergency department (ED); 35 subjects (6.1%) were direct admissions. Among re-admitted subjects, 44 had device implantation, 36 underwent surgical resection, and 14 underwent LITT. 4 subjects (0.70%) had two or more admissions. After adjusting for age, sex, and post-operative risk factors, subjects undergoing device implantation were less likely to be readmitted from the ED within 30 days of index admission compared to subjects undergoing resection [OR: 0.523, 95% CI: 0.286-0.948, p=0.0328], but no significant difference was observed between subjects receiving LITT versus resection [OR: 1.314, 95% CI: 0.583-2.894, p=0.4739].

Conclusions The overall 30-day readmission rate from the ED following surgical intervention for DRE is 17.0%. Resection-based procedures were associated with higher 30-day readmission rates compared to device implantation.

Authors/Disclosures
Rohit Das, MD, FAAN (VA Portland Healthcare System) PRESENTER	Dr. Das has received personal compensation for serving as an employee of Oregon Health Science University. Dr. Das has received personal compensation in the range of $10,000-$49,999 for serving as a Physician Advisor with Concentra .
Kevin Shan, MD	Mr. Shan has nothing to disclose.
Ryan Hays, MD, MBA, FAES, FAAN (UT Southwestern Medical Center)	Dr. Hays has nothing to disclose.
Sasha Alick-Lindstrom, MD, MPH FACNS, FAES, FAAN (UT Southwestern Medical Center)	Dr. Alick-Lindstrom has nothing to disclose.
Kan Ding, MD (UT Southwestern Medical Center)	The institution of Dr. Ding has received research support from National Institute of Aging. The institution of Dr. Ding has received research support from NINDS.
Bradley Lega, MD (UT Southwestern)	The institution of Bradley Lega has received research support from NIH.
Irina Podkorytova	Irina Podkorytova has nothing to disclose.
J. H. Harvey, DO (UT Southwestern Medical Center)	Dr. Harvey has received personal compensation for serving as an employee of Neuralogix. Dr. Harvey has received personal compensation for serving as an employee of Integris . Dr. Harvey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceuticals. Dr. Harvey has stock in Epiminder.
Mark Agostini, MD (U.T. Southwestern Medical Center)	Dr. Agostini has nothing to disclose.
Ghazala Perven, MD (UT Southwestern Medical Center)	Dr. Perven has nothing to disclose.
Marisara Dieppa, MD (University of Texas SW Medical School)	Dr. Dieppa has nothing to disclose.
Alexander Doyle, MD (University of Texas SW Medical School)	Dr. Doyle has nothing to disclose.
Rodrigo Zepeda, MD (University of Texas Southwestern)	The institution of Dr. Zepeda has received research support from NIH.

��ɫ��

��ɫ��